The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...
This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
A narrative review,” published in the September 2024 issue of Pulmonology by Chilosi et al. In recent decades, idiopathic interstitial pneumonia (IIPs) classification has primarily relied on clinical, ...
The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback